Evolution in Massive and Sub-Massive Pulmonary Embolism Treatment Part 2
April 1, 2021 - April 1, 2022
The webinar is designed to meet the needs of cardiologists, surgeons, internists, residents, fellows in training, nurses, nurse practitioners, physician assistants, pharmacists, health care technicians, and other health care providers and investigators who participate in the management of patients with coronary, peripheral, structural, and arrhythmic cardiovascular diseases.
The purpose of this educational activity is to provide participants with knowledge of acute pulmonary embolism treatment.
- Explain the importance of PERT program and its importance on clinical outcomes
- Discuss the components of a system wide PERT program and how it can be functional
- Identify best patients for anticoagulation alone, lysis, endovascular embolectomy, or systemic lysis
- List steps for catheter directed pharmaco-mechanical lysis, including facilitated lysis
- List steps for endovascular thrombectomy
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of CMEsolutions and Cardiovascular Innovations Foundation. The CMEsolutions is accredited by the ACCME to provide continuing medical education for physicians.
The CMEsolutions designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Start Date: April 1, 2021 End Date: April 1, 2022
- Read CME Information
- Participate in virtual presentations
- Logon to the following URL: https://online-med-edu.com/cvievolution/412021 (you are here)
- Complete evaluation, credit request form, and download or print credit statement
Faculty and Disclosures
CMEsolutions requires everyone in a position to control the content of this activity to disclose any relevant financial conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by CMEsolutions for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. CMEsolutions has mitigated all conflicts of interest prior to this educational activity.
Subhash Banerjee, MD
Chief of Cardiology, VA North Texas Health Care System
Disclosed the following relevant financial relationships: AstraZeneca-Speaker’s Bureau; Boston Scientific- Institutional Research Grant; Livmore Inc.-Consultant
Christopher Morris Huff, MD
Interventional Cardiologist, Riverside Methodist Hospital
Disclosed the following relevant financial relationships: Inari Medical-Speaking, Teaching, Consulting; Surmodics-Consulting; Boston Scientific-Speaking, Teaching
Jay Giri, MD
Cardiologist, Penn Medicine
Disclosed the following relevant financial relationships: Inari, Boston Scientific-Advisory Board
Jun Li, MD
Interventional Cardiology, University Hospitals
Disclosed the following relevant financial relationships: Medtronic, Inari Medical-Advisory Board; Abbott Vascular, Philips-Consultant
Mehdi Shishehbor, DO, MPH, PhD
Director, Cardiovascular Interventional Center, University Hospitals Cleveland Medical Center
Mehdi Shishehbor has no relevant financial relationships to disclose.
No member of CMEsolutions or Cardiovascular Innovations Foundation has any relevant financial relationships to disclose.
This activitymay contain discussion of unlabeled and/or investigational uses of agents not approved by the FDA. Please consult the prescribing information for each product.